Log in
OTCMKTS:INTI

Inhibitor Therapeutics Stock Forecast, Price & News

$0.06
0.00 (0.00 %)
(As of 10/21/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.05
Now: $0.06
$0.06
50-Day Range N/A
52-Week Range
$0.01
Now: $0.06
$0.14
Volume70,000 shs
Average Volume36,139 shs
Market Capitalization$20.55 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.24
Inhibitor Therapeutics Inc. operates as a pharmaceutical development company that discovers, develops, and plans to commercialize therapeutics to inhibit the progression of cancerous and non-cancerous proliferation disorders in the United States. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including cell differentiation, tissue polarity, and cell proliferation. It focuses on developing its lead product, SUBA-Itraconazole, a patented oral formulation for prostate and lung cancer. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics Inc. in August 2019. Inhibitor Therapeutics Inc. was founded in 1992 and is based in Tampa, Florida.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.00 out of 5 stars

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:INTI
CUSIPN/A
CIKN/A
Phone813 864 2559
Employees2

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.02) per share

Profitability

Net Income$-2,730,000.00

Miscellaneous

Market Cap$20.55 million
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
$0.06
0.00 (0.00 %)
(As of 10/21/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INTI News and Ratings via Email

Sign-up to receive the latest news and ratings for INTI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Inhibitor Therapeutics (OTCMKTS:INTI) Frequently Asked Questions

When is Inhibitor Therapeutics' next earnings date?

Inhibitor Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Inhibitor Therapeutics
.

Who are some of Inhibitor Therapeutics' key competitors?

Who are Inhibitor Therapeutics' key executives?

Inhibitor Therapeutics' management team includes the following people:
  • Mr. Nicholas Jon Virca, Pres & CEO (Age 74, Pay $327.43k)
  • Mr. Garrison J. Hasara CPA, CPA, CFO, Treasurer, Corp. Sec. & Chief Compliance Officer (Age 51, Pay $253.6k)

What is Inhibitor Therapeutics' stock symbol?

Inhibitor Therapeutics trades on the OTCMKTS under the ticker symbol "INTI."

How do I buy shares of Inhibitor Therapeutics?

Shares of INTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Inhibitor Therapeutics' stock price today?

One share of INTI stock can currently be purchased for approximately $0.06.

How big of a company is Inhibitor Therapeutics?

Inhibitor Therapeutics has a market capitalization of $20.55 million. Inhibitor Therapeutics employs 2 workers across the globe.

What is Inhibitor Therapeutics' official website?

The official website for Inhibitor Therapeutics is www.inhibitortx.com.

How can I contact Inhibitor Therapeutics?

Inhibitor Therapeutics' mailing address is 4830 W. Kennedy Blvd. Suite 600, Tampa FL, 33609. The company can be reached via phone at 813 864 2559 or via email at [email protected]

This page was last updated on 10/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.